<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01505673</url>
  </required_header>
  <id_info>
    <org_study_id>IIS-000235</org_study_id>
    <nct_id>NCT01505673</nct_id>
  </id_info>
  <brief_title>Adding Liraglutide to High Dose Insulin: Breaking the Cycle</brief_title>
  <official_title>Adding Liraglutide to High Dose Insulin: Breaking the Cycle</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ildiko Lingvay</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether the addition of liraglutide 1.8 mg/day to a
      high-dose insulin regimen (&gt;1.8 units/kg/day) in patients with uncontrolled (HbA1c &gt;7.5%)
      type 2 diabetes mellitus will improve blood sugar control.

      It also evaluates the effect of liraglutide on liver and pancreatic fat content, explores the
      mechanism of blood sugar improvement by assessing weight and pancreatic hormone release, and
      assesses blood pressure, lipid profile, and liver function. Finally it will look at patient
      quality of life and safety.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type 2 diabetes is a progressive disease with incessant beta-cell dysfunction that often
      ultimately requires insulin treatment. Patients requiring high insulin dosages represent a
      particular treatment challenge and often have uncontrolled glycemia despite progressive dose
      increases and are especially prone to insulin related lipotoxicity and weight gain.

      Glucagon-like peptide agonists (GLP-1) such as liraglutide have many actions that position
      them to break the vicious cycle in this population through the following mechanisms: (1)
      weight loss; (2) improved hepatic steatosis; (3) improved pancreatic steatosis; (4) decreased
      glucagon levels; (5) improved beta-cell function.

      The purpose of the study is to demonstrate that liraglutide is both effective and safe when
      added to a high dose insulin treatment regimen. Liraglutide will improve glycemic control,
      weight, metabolic parameters, as well as patient satisfaction, with minimal adverse events.
      The study also proposes to study the mechanisms through which such improvements might occur,
      especially beta-cell function, glucagon levels, and hepatic and pancreatic fat content.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glycemic Control Measured by HbA1c</measure>
    <time_frame>6-months</time_frame>
    <description>HbA1c (%)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pancreatic and Hepatic Triglyceride Content</measure>
    <time_frame>6-months</time_frame>
    <description>Liver Triglyceride and Pancreatic Triglyceride</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight</measure>
    <time_frame>6-months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beta-Cell Function</measure>
    <time_frame>6-months</time_frame>
    <description>Fasting Glucose as a Measure of Beta-Cell Function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucagon</measure>
    <time_frame>6-months</time_frame>
    <description>Measured during mixed meal challenge test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Daily Insulin Dose</measure>
    <time_frame>6-months</time_frame>
    <description>The 3 days average of the total daily dose of insulin used within 3 consecutive days prior office visit 6 month.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Daily Injections</measure>
    <time_frame>6-months</time_frame>
    <description>The 3 days average of the number of daily injections performed within 3 consecutive days prior office visit 6 month.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>6-months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid Profile</measure>
    <time_frame>6-months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver Function Blood Test</measure>
    <time_frame>6-months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemic Events</measure>
    <time_frame>6-months</time_frame>
    <description>Reported as hypoglycemic events per month by patient as any blood glucose &lt;70 mg/dl or symptoms of hypoglycemia with blood glucose &gt;70 mg/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Survey (QoL) - General Health Perception</measure>
    <time_frame>6-months</time_frame>
    <description>General health perception was measured at randomization and 6 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 1-5, where 1 = excellent; 2 = very good; 3 = good; 4 = fair; 5 = poor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beta-Cell Function</measure>
    <time_frame>6 months</time_frame>
    <description>Fasting C-peptide as a Measure of Beta-Cell Function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Matsuda Index as a Measure of Beta Cell Function</measure>
    <time_frame>6 months</time_frame>
    <description>The Matsuda index is a measure of insulin sensitivity and has no minimum/maximum values. Index values are calculated as 500,000/square root of ((fasting glucose x fasting c-peptide x 333) x (mean 120 min post-meal glucose x mean 120 min post-meal c-peptide x 333)). Higher/lower values = better/worse insulin sensitivity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beta-cell Function</measure>
    <time_frame>6 Months</time_frame>
    <description>AUC c-peptide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio (AUC C-peptide/AUC Glucose)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC Glucose</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Survey (QoL) - Current Health Perception</measure>
    <time_frame>6 months</time_frame>
    <description>Current health perception was measured at randomization and 6 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 1-5, where 1 = much better than 3 months ago; 2 - Somewhat better now than 3 months ago; 3 - About the same; 4 - Somewhat worse now than 3 months ago; 5 Much worse now than 3 months ago.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Survey (QoL) - Treatment Satisfaction</measure>
    <time_frame>6 months</time_frame>
    <description>Quality of Life Survey (QoL) - treatment satisfactionTreatment satisfaction was measured at randomization and 6 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 1-5, where 1 - very satisfied; 2 - moderately satisfied; 3 - neither satisfied nor dissatisfied; 4 - moderately dissatisfied; 5 - very dissatisfied.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Survey (QoL) - Treatment Impact</measure>
    <time_frame>6 months</time_frame>
    <description>Treatment impact was measured at randomization and 6 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 1-5, where 1 - very satisfied; 2 - moderately satisfied; 3 - neither satisfied nor dissatisfied; 4 - moderately dissatisfied; 5 - very dissatisfied.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Survey (QoL) - Social or Vocational Worry</measure>
    <time_frame>6 months</time_frame>
    <description>Social or vocational worry was measured at randomization and 6 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 0-5, where 0 - does not apply; 1 - never; 2 - seldom; 3 - sometimes; 4 - often; 5 - all of the time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Survey (QoL) - Hypoglycemia Fear</measure>
    <time_frame>6 months</time_frame>
    <description>Hypoglycemia fear was measured at randomization and 6 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 1-5, where 1 - never worry; 2 - rarely water; 3 - sometimes worry; 4 - often worry; 5 - very often worry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Survey (QoL) - Glycemia Control Perception</measure>
    <time_frame>6 months</time_frame>
    <description>Glycemia control perception was measured at randomization and 6 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a scale score of 1-7, where 1 - extremely controlled and 7 - not at all controlled.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Survey (QoL) - Lifestyle Flexibility</measure>
    <time_frame>6 months</time_frame>
    <description>Lifestyle flexibility was measured at randomization and 6 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 1 to 5, where 1 - a great deal of choice; 2 - a lot of choice; 3 - some choice; 4 - a little choice; 5 - no choice.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Survey (QoL) - Social Stigma</measure>
    <time_frame>6 months</time_frame>
    <description>Social stigma was measured at randomization and 6 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 1 to 5, where 1 strongly agree; 2 - somewhat agree; 3 - neither agree nor disagree; 4 - somewhat disagree; 5 - strongly disagree.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Survey (QoL) - Satisfaction With Insulin Treatment</measure>
    <time_frame>6 months</time_frame>
    <description>Satisfaction with insulin treatment was measured at randomization and 6 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a scale score of 1 to 7, where 1 extremely satisfied to 7 - not at all satisfied.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Survey (QoL) - Willingness to Continue Insulin Treatment</measure>
    <time_frame>6 months</time_frame>
    <description>Willingness to continue insulin treatment was measured at randomization and 6 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a scale score of 1 to 7, where 1 extremely willing to 7 - not at all willing.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Liraglutide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline injection</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide</intervention_name>
    <description>Liraglutdie 1.8mg injected subcutaneously from pen device once daily for 6-months</description>
    <arm_group_label>Liraglutide</arm_group_label>
    <other_name>Victoza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Placebo injection of 1.8mg saline once daily for 6-months</description>
    <arm_group_label>Saline injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes mellitus

          -  Insulin dose of &gt;1.8 units/kg/day (represents total daily insulin dose, regardless of
             formulation, regimen, number of daily shots)

          -  HbA1c ≥ 7.5% and ≤ 11%

          -  Age ≥ 18

          -  Stable comorbidities on stable treatment regimens

          -  Stable dose of all oral hypoglycemics for ≥ 3 months prior to enrollment

          -  Ability to provide informed consent before any trial-related activities

        Exclusion Criteria:

          -  Type 1 diabetes mellitus

          -  Any contraindication to the MRI procedure (metallic implants, severe claustrophobia,
             pregnancy, unable to lie still on a hard table for the duration of the procedure,
             weight above 400 lb - limit of the MRI table, magnet's inner circumference smaller
             than the largest body circumference)

          -  History of any pancreatic disease as it might interfere with the pancreatic TG
             measurement (i.e. pancreatitis, tumors, cysts, type 1 diabetes, any pancreatic
             surgery)

          -  End Stage Renal Disease on dialysis due to increased risk of hypoglycemia, and
             possible interference with accurate measurement of HbA1c

          -  Incretin therapy (any GLP-1 agonist or DPP-IV inhibitor)

          -  Unstable or decompensated comorbidities

          -  Personal or family history of medullary thyroid carcinoma or MEN-2 syndrome

          -  Severe gastroparesis

          -  Pregnancy, breast feeding, intention to become pregnant, or not using adequate
             contraceptive measures

          -  Organ transplant recipient or waiting list candidate

          -  Steroid use (current or potential use during the trial)

          -  Known/suspected allergy to trial medication, excipients, or related products

          -  Contraindications to study medications, worded specifically as stated in the product's
             prescribing information

          -  Non-English speaking volunteers since no interpreters are available and the safety of
             the volunteers could be jeopardized if adequate and reliable communication is not
             possible.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ildiko Lingvay, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Southwestern</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2012</study_first_submitted>
  <study_first_submitted_qc>January 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2012</study_first_posted>
  <results_first_submitted>August 1, 2017</results_first_submitted>
  <results_first_submitted_qc>November 14, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 15, 2017</results_first_posted>
  <last_update_submitted>December 15, 2017</last_update_submitted>
  <last_update_submitted_qc>December 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Ildiko Lingvay</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Insulin</keyword>
  <keyword>Glucagon-like peptide</keyword>
  <keyword>Liraglutide</keyword>
  <keyword>Beta-Cell</keyword>
  <keyword>pancreatic steatosis</keyword>
  <keyword>hepatic steatosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Liraglutide</title>
          <description>Liraglutide: Liraglutdie 1.8mg injected subcutaneously from pen device once daily for 6-months</description>
        </group>
        <group group_id="P2">
          <title>Saline Injection</title>
          <description>Saline: Placebo injection of 1.8mg saline once daily for 6-months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Liraglutide</title>
          <description>Liraglutide: Liraglutdie 1.8mg injected subcutaneously from pen device once daily for 6-months</description>
        </group>
        <group group_id="B2">
          <title>Saline Injection</title>
          <description>Saline: Placebo injection of 1.8mg saline once daily for 6-months</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
            <count group_id="B2" value="36"/>
            <count group_id="B3" value="71"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.8" spread="8.1"/>
                    <measurement group_id="B2" value="55.5" spread="6.6"/>
                    <measurement group_id="B3" value="54.2" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Glycemic Control Measured by HbA1c</title>
        <description>HbA1c (%)</description>
        <time_frame>6-months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Liraglutide: Liraglutdie 1.8mg injected subcutaneously from pen device once daily for 6-months</description>
          </group>
          <group group_id="O2">
            <title>Saline Injection</title>
            <description>Saline: Placebo injection of 1.8mg saline once daily for 6-months</description>
          </group>
        </group_list>
        <measure>
          <title>Glycemic Control Measured by HbA1c</title>
          <description>HbA1c (%)</description>
          <units>Percent HbA1c</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9" spread="1.1"/>
                    <measurement group_id="O2" value="8.9" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pancreatic and Hepatic Triglyceride Content</title>
        <description>Liver Triglyceride and Pancreatic Triglyceride</description>
        <time_frame>6-months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Liraglutide: Liraglutdie 1.8mg injected subcutaneously from pen device once daily for 6-months</description>
          </group>
          <group group_id="O2">
            <title>Saline Injection</title>
            <description>Saline: Placebo injection of 1.8mg saline once daily for 6-months</description>
          </group>
        </group_list>
        <measure>
          <title>Pancreatic and Hepatic Triglyceride Content</title>
          <description>Liver Triglyceride and Pancreatic Triglyceride</description>
          <units>Percent Triglyceride</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Liver Triglyceride</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.3" spread="5.8"/>
                    <measurement group_id="O2" value="12.2" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pancreatic Triglyceride</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.53" spread="8.13"/>
                    <measurement group_id="O2" value="14.64" spread="9.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weight</title>
        <time_frame>6-months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Liraglutide: Liraglutdie 1.8mg injected subcutaneously from pen device once daily for 6-months</description>
          </group>
          <group group_id="O2">
            <title>Saline Injection</title>
            <description>Saline: Placebo injection of 1.8mg saline once daily for 6-months</description>
          </group>
        </group_list>
        <measure>
          <title>Weight</title>
          <units>Kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114" spread="21"/>
                    <measurement group_id="O2" value="117" spread="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Beta-Cell Function</title>
        <description>Fasting Glucose as a Measure of Beta-Cell Function</description>
        <time_frame>6-months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Liraglutide: Liraglutdie 1.8mg injected subcutaneously from pen device once daily for 6-months</description>
          </group>
          <group group_id="O2">
            <title>Saline Injection</title>
            <description>Saline: Placebo injection of 1.8mg saline once daily for 6-months</description>
          </group>
        </group_list>
        <measure>
          <title>Beta-Cell Function</title>
          <description>Fasting Glucose as a Measure of Beta-Cell Function</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="179" spread="75"/>
                    <measurement group_id="O2" value="197" spread="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucagon</title>
        <description>Measured during mixed meal challenge test.</description>
        <time_frame>6-months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Liraglutide: Liraglutdie 1.8mg injected subcutaneously from pen device once daily for 6-months</description>
          </group>
          <group group_id="O2">
            <title>Saline Injection</title>
            <description>Saline: Placebo injection of 1.8mg saline once daily for 6-months</description>
          </group>
        </group_list>
        <measure>
          <title>Glucagon</title>
          <description>Measured during mixed meal challenge test.</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107.3" spread="44.5"/>
                    <measurement group_id="O2" value="93.8" spread="37.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Daily Insulin Dose</title>
        <description>The 3 days average of the total daily dose of insulin used within 3 consecutive days prior office visit 6 month.</description>
        <time_frame>6-months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Liraglutide: Liraglutdie 1.8mg injected subcutaneously from pen device once daily for 6-months</description>
          </group>
          <group group_id="O2">
            <title>Saline Injection</title>
            <description>Saline: Placebo injection of 1.8mg saline once daily for 6-months</description>
          </group>
        </group_list>
        <measure>
          <title>Total Daily Insulin Dose</title>
          <description>The 3 days average of the total daily dose of insulin used within 3 consecutive days prior office visit 6 month.</description>
          <units>IU</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="200" lower_limit="163" upper_limit="275"/>
                    <measurement group_id="O2" value="218" lower_limit="160" upper_limit="260"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Daily Injections</title>
        <description>The 3 days average of the number of daily injections performed within 3 consecutive days prior office visit 6 month.</description>
        <time_frame>6-months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Liraglutide: Liraglutdie 1.8mg injected subcutaneously from pen device once daily for 6-months</description>
          </group>
          <group group_id="O2">
            <title>Saline Injection</title>
            <description>Saline: Placebo injection of 1.8mg saline once daily for 6-months</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Daily Injections</title>
          <description>The 3 days average of the number of daily injections performed within 3 consecutive days prior office visit 6 month.</description>
          <units>number/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="1.4"/>
                    <measurement group_id="O2" value="3.8" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Pressure</title>
        <time_frame>6-months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Liraglutide: Liraglutdie 1.8mg injected subcutaneously from pen device once daily for 6-months</description>
          </group>
          <group group_id="O2">
            <title>Saline Injection</title>
            <description>Saline: Placebo injection of 1.8mg saline once daily for 6-months</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134" spread="18"/>
                    <measurement group_id="O2" value="135" spread="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.5" spread="13.7"/>
                    <measurement group_id="O2" value="74.3" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lipid Profile</title>
        <time_frame>6-months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Liraglutide: Liraglutdie 1.8mg injected subcutaneously from pen device once daily for 6-months</description>
          </group>
          <group group_id="O2">
            <title>Saline Injection</title>
            <description>Saline: Placebo injection of 1.8mg saline once daily for 6-months</description>
          </group>
        </group_list>
        <measure>
          <title>Lipid Profile</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154" spread="41"/>
                    <measurement group_id="O2" value="152" spread="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.9" spread="37.2"/>
                    <measurement group_id="O2" value="76.3" spread="28.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.6" spread="9.8"/>
                    <measurement group_id="O2" value="37.6" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Liver Function Blood Test</title>
        <time_frame>6-months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Liraglutide: Liraglutdie 1.8mg injected subcutaneously from pen device once daily for 6-months</description>
          </group>
          <group group_id="O2">
            <title>Saline Injection</title>
            <description>Saline: Placebo injection of 1.8mg saline once daily for 6-months</description>
          </group>
        </group_list>
        <measure>
          <title>Liver Function Blood Test</title>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.8" spread="13.5"/>
                    <measurement group_id="O2" value="36.0" spread="43.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.4" spread="17.6"/>
                    <measurement group_id="O2" value="32.1" spread="30.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hypoglycemic Events</title>
        <description>Reported as hypoglycemic events per month by patient as any blood glucose &lt;70 mg/dl or symptoms of hypoglycemia with blood glucose &gt;70 mg/dl</description>
        <time_frame>6-months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Liraglutide: Liraglutdie 1.8mg injected subcutaneously from pen device once daily for 6-months</description>
          </group>
          <group group_id="O2">
            <title>Saline Injection</title>
            <description>Saline: Placebo injection of 1.8mg saline once daily for 6-months</description>
          </group>
        </group_list>
        <measure>
          <title>Hypoglycemic Events</title>
          <description>Reported as hypoglycemic events per month by patient as any blood glucose &lt;70 mg/dl or symptoms of hypoglycemia with blood glucose &gt;70 mg/dl</description>
          <units>events per month per patient</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" lower_limit="0.7" upper_limit="1.7"/>
                    <measurement group_id="O2" value="0.7" lower_limit="0.5" upper_limit="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Survey (QoL) - General Health Perception</title>
        <description>General health perception was measured at randomization and 6 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 1–5, where 1 = excellent; 2 = very good; 3 = good; 4 = fair; 5 = poor.</description>
        <time_frame>6-months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Liraglutide: Liraglutdie 1.8mg injected subcutaneously from pen device once daily for 6-months</description>
          </group>
          <group group_id="O2">
            <title>Saline Injection</title>
            <description>Saline: Placebo injection of 1.8mg saline once daily for 6-months</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Survey (QoL) - General Health Perception</title>
          <description>General health perception was measured at randomization and 6 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 1–5, where 1 = excellent; 2 = very good; 3 = good; 4 = fair; 5 = poor.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="0.9"/>
                    <measurement group_id="O2" value="3.6" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Beta-Cell Function</title>
        <description>Fasting C-peptide as a Measure of Beta-Cell Function</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Liraglutide: Liraglutdie 1.8mg injected subcutaneously from pen device once daily for 6-months</description>
          </group>
          <group group_id="O2">
            <title>Saline Injection</title>
            <description>Saline: Placebo injection of 1.8mg saline once daily for 6-months</description>
          </group>
        </group_list>
        <measure>
          <title>Beta-Cell Function</title>
          <description>Fasting C-peptide as a Measure of Beta-Cell Function</description>
          <units>microgram/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.48" spread="1.18"/>
                    <measurement group_id="O2" value="1.75" spread="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Matsuda Index as a Measure of Beta Cell Function</title>
        <description>The Matsuda index is a measure of insulin sensitivity and has no minimum/maximum values. Index values are calculated as 500,000/square root of ((fasting glucose x fasting c-peptide x 333) x (mean 120 min post-meal glucose x mean 120 min post-meal c-peptide x 333)). Higher/lower values = better/worse insulin sensitivity.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Liraglutide: Liraglutdie 1.8mg injected subcutaneously from pen device once daily for 6-months</description>
          </group>
          <group group_id="O2">
            <title>Saline Injection</title>
            <description>Saline: Placebo injection of 1.8mg saline once daily for 6-months</description>
          </group>
        </group_list>
        <measure>
          <title>Matsuda Index as a Measure of Beta Cell Function</title>
          <description>The Matsuda index is a measure of insulin sensitivity and has no minimum/maximum values. Index values are calculated as 500,000/square root of ((fasting glucose x fasting c-peptide x 333) x (mean 120 min post-meal glucose x mean 120 min post-meal c-peptide x 333)). Higher/lower values = better/worse insulin sensitivity.</description>
          <units>index</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.88" lower_limit="1.67" upper_limit="3.70"/>
                    <measurement group_id="O2" value="3.12" lower_limit="1.78" upper_limit="9.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Beta-cell Function</title>
        <description>AUC c-peptide</description>
        <time_frame>6 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Liraglutide: Liraglutdie 1.8mg injected subcutaneously from pen device once daily for 6-months</description>
          </group>
          <group group_id="O2">
            <title>Saline Injection</title>
            <description>Saline: Placebo injection of 1.8mg saline once daily for 6-months</description>
          </group>
        </group_list>
        <measure>
          <title>Beta-cell Function</title>
          <description>AUC c-peptide</description>
          <units>ug/(L/min)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1234.6" spread="588.6"/>
                    <measurement group_id="O2" value="922.9" spread="470.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ratio (AUC C-peptide/AUC Glucose)</title>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Liraglutide: Liraglutdie 1.8mg injected subcutaneously from pen device once daily for 6-months</description>
          </group>
          <group group_id="O2">
            <title>Saline Injection</title>
            <description>Saline: Placebo injection of 1.8mg saline once daily for 6-months</description>
          </group>
        </group_list>
        <measure>
          <title>Ratio (AUC C-peptide/AUC Glucose)</title>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.019" spread="0.010"/>
                    <measurement group_id="O2" value="0.013" spread="0.008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC Glucose</title>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Liraglutide: Liraglutdie 1.8mg injected subcutaneously from pen device once daily for 6-months</description>
          </group>
          <group group_id="O2">
            <title>Saline Injection</title>
            <description>Saline: Placebo injection of 1.8mg saline once daily for 6-months</description>
          </group>
        </group_list>
        <measure>
          <title>AUC Glucose</title>
          <units>mg/(dL/min)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71747" spread="22141"/>
                    <measurement group_id="O2" value="79278" spread="29416"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Survey (QoL) - Current Health Perception</title>
        <description>Current health perception was measured at randomization and 6 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 1–5, where 1 = much better than 3 months ago; 2 - Somewhat better now than 3 months ago; 3 - About the same; 4 - Somewhat worse now than 3 months ago; 5 Much worse now than 3 months ago.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Liraglutide: Liraglutdie 1.8mg injected subcutaneously from pen device once daily for 6-months</description>
          </group>
          <group group_id="O2">
            <title>Saline Injection</title>
            <description>Saline: Placebo injection of 1.8mg saline once daily for 6-months</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Survey (QoL) - Current Health Perception</title>
          <description>Current health perception was measured at randomization and 6 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 1–5, where 1 = much better than 3 months ago; 2 - Somewhat better now than 3 months ago; 3 - About the same; 4 - Somewhat worse now than 3 months ago; 5 Much worse now than 3 months ago.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="0.9"/>
                    <measurement group_id="O2" value="2.6" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Survey (QoL) - Treatment Satisfaction</title>
        <description>Quality of Life Survey (QoL) - treatment satisfactionTreatment satisfaction was measured at randomization and 6 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 1–5, where 1 - very satisfied; 2 - moderately satisfied; 3 - neither satisfied nor dissatisfied; 4 - moderately dissatisfied; 5 - very dissatisfied.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Liraglutide: Liraglutdie 1.8mg injected subcutaneously from pen device once daily for 6-months</description>
          </group>
          <group group_id="O2">
            <title>Saline Injection</title>
            <description>Saline: Placebo injection of 1.8mg saline once daily for 6-months</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Survey (QoL) - Treatment Satisfaction</title>
          <description>Quality of Life Survey (QoL) - treatment satisfactionTreatment satisfaction was measured at randomization and 6 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 1–5, where 1 - very satisfied; 2 - moderately satisfied; 3 - neither satisfied nor dissatisfied; 4 - moderately dissatisfied; 5 - very dissatisfied.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="0.8"/>
                    <measurement group_id="O2" value="2.7" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Survey (QoL) - Treatment Impact</title>
        <description>Treatment impact was measured at randomization and 6 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 1–5, where 1 - very satisfied; 2 - moderately satisfied; 3 - neither satisfied nor dissatisfied; 4 - moderately dissatisfied; 5 - very dissatisfied.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Liraglutide: Liraglutdie 1.8mg injected subcutaneously from pen device once daily for 6-months</description>
          </group>
          <group group_id="O2">
            <title>Saline Injection</title>
            <description>Saline: Placebo injection of 1.8mg saline once daily for 6-months</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Survey (QoL) - Treatment Impact</title>
          <description>Treatment impact was measured at randomization and 6 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 1–5, where 1 - very satisfied; 2 - moderately satisfied; 3 - neither satisfied nor dissatisfied; 4 - moderately dissatisfied; 5 - very dissatisfied.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="0.5"/>
                    <measurement group_id="O2" value="2.6" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Survey (QoL) - Social or Vocational Worry</title>
        <description>Social or vocational worry was measured at randomization and 6 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 0–5, where 0 - does not apply; 1 - never; 2 - seldom; 3 - sometimes; 4 - often; 5 - all of the time.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Liraglutide: Liraglutdie 1.8mg injected subcutaneously from pen device once daily for 6-months</description>
          </group>
          <group group_id="O2">
            <title>Saline Injection</title>
            <description>Saline: Placebo injection of 1.8mg saline once daily for 6-months</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Survey (QoL) - Social or Vocational Worry</title>
          <description>Social or vocational worry was measured at randomization and 6 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 0–5, where 0 - does not apply; 1 - never; 2 - seldom; 3 - sometimes; 4 - often; 5 - all of the time.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="0.7"/>
                    <measurement group_id="O2" value="1.0" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Survey (QoL) - Hypoglycemia Fear</title>
        <description>Hypoglycemia fear was measured at randomization and 6 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 1–5, where 1 - never worry; 2 - rarely water; 3 - sometimes worry; 4 - often worry; 5 - very often worry.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Liraglutide: Liraglutdie 1.8mg injected subcutaneously from pen device once daily for 6-months</description>
          </group>
          <group group_id="O2">
            <title>Saline Injection</title>
            <description>Saline: Placebo injection of 1.8mg saline once daily for 6-months</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Survey (QoL) - Hypoglycemia Fear</title>
          <description>Hypoglycemia fear was measured at randomization and 6 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 1–5, where 1 - never worry; 2 - rarely water; 3 - sometimes worry; 4 - often worry; 5 - very often worry.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="0.7"/>
                    <measurement group_id="O2" value="2.0" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Survey (QoL) - Glycemia Control Perception</title>
        <description>Glycemia control perception was measured at randomization and 6 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a scale score of 1–7, where 1 - extremely controlled and 7 - not at all controlled.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Liraglutide: Liraglutdie 1.8mg injected subcutaneously from pen device once daily for 6-months</description>
          </group>
          <group group_id="O2">
            <title>Saline Injection</title>
            <description>Saline: Placebo injection of 1.8mg saline once daily for 6-months</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Survey (QoL) - Glycemia Control Perception</title>
          <description>Glycemia control perception was measured at randomization and 6 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a scale score of 1–7, where 1 - extremely controlled and 7 - not at all controlled.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="1.0"/>
                    <measurement group_id="O2" value="2.9" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Survey (QoL) - Lifestyle Flexibility</title>
        <description>Lifestyle flexibility was measured at randomization and 6 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 1 to 5, where 1 - a great deal of choice; 2 - a lot of choice; 3 - some choice; 4 - a little choice; 5 - no choice.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Liraglutide: Liraglutdie 1.8mg injected subcutaneously from pen device once daily for 6-months</description>
          </group>
          <group group_id="O2">
            <title>Saline Injection</title>
            <description>Saline: Placebo injection of 1.8mg saline once daily for 6-months</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Survey (QoL) - Lifestyle Flexibility</title>
          <description>Lifestyle flexibility was measured at randomization and 6 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 1 to 5, where 1 - a great deal of choice; 2 - a lot of choice; 3 - some choice; 4 - a little choice; 5 - no choice.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="0.9"/>
                    <measurement group_id="O2" value="2.6" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Survey (QoL) - Social Stigma</title>
        <description>Social stigma was measured at randomization and 6 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 1 to 5, where 1 strongly agree; 2 - somewhat agree; 3 - neither agree nor disagree; 4 - somewhat disagree; 5 - strongly disagree.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Liraglutide: Liraglutdie 1.8mg injected subcutaneously from pen device once daily for 6-months</description>
          </group>
          <group group_id="O2">
            <title>Saline Injection</title>
            <description>Saline: Placebo injection of 1.8mg saline once daily for 6-months</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Survey (QoL) - Social Stigma</title>
          <description>Social stigma was measured at randomization and 6 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 1 to 5, where 1 strongly agree; 2 - somewhat agree; 3 - neither agree nor disagree; 4 - somewhat disagree; 5 - strongly disagree.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="1.1"/>
                    <measurement group_id="O2" value="2.4" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Survey (QoL) - Satisfaction With Insulin Treatment</title>
        <description>Satisfaction with insulin treatment was measured at randomization and 6 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a scale score of 1 to 7, where 1 extremely satisfied to 7 - not at all satisfied.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Liraglutide: Liraglutdie 1.8mg injected subcutaneously from pen device once daily for 6-months</description>
          </group>
          <group group_id="O2">
            <title>Saline Injection</title>
            <description>Saline: Placebo injection of 1.8mg saline once daily for 6-months</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Survey (QoL) - Satisfaction With Insulin Treatment</title>
          <description>Satisfaction with insulin treatment was measured at randomization and 6 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a scale score of 1 to 7, where 1 extremely satisfied to 7 - not at all satisfied.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="1.0"/>
                    <measurement group_id="O2" value="2.3" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Survey (QoL) - Willingness to Continue Insulin Treatment</title>
        <description>Willingness to continue insulin treatment was measured at randomization and 6 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a scale score of 1 to 7, where 1 extremely willing to 7 - not at all willing.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Liraglutide: Liraglutdie 1.8mg injected subcutaneously from pen device once daily for 6-months</description>
          </group>
          <group group_id="O2">
            <title>Saline Injection</title>
            <description>Saline: Placebo injection of 1.8mg saline once daily for 6-months</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Survey (QoL) - Willingness to Continue Insulin Treatment</title>
          <description>Willingness to continue insulin treatment was measured at randomization and 6 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a scale score of 1 to 7, where 1 extremely willing to 7 - not at all willing.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="0.5"/>
                    <measurement group_id="O2" value="2.1" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <desc>Not available</desc>
      <group_list>
        <group group_id="E1">
          <title>Liraglutide</title>
          <description>Liraglutide: Liraglutide 1.8mg injected subcutaneously from pen device once daily for 6-months</description>
        </group>
        <group group_id="E2">
          <title>Saline Injection</title>
          <description>Saline: Placebo injection of 1.8mg saline once daily for 6-months</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrilation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Stent placement</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COPD exacerbation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="35"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="35"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Decreased in apetite</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="35"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Increase of serum amylase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Hoarseness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Shortness of breath</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Ildiko Lingvay</name_or_title>
      <organization>University of Texas Southwestern Medical Center at Dallas</organization>
      <phone>214-648-2779</phone>
      <email>ildiko.lingvay@utsouthwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

